Literature DB >> 1970493

Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle.

I Muramatsu1, T Ohmura, S Kigoshi, S Hashimoto, M Oshita.   

Abstract

1. We examined whether alpha 1-adrenoceptors in various blood vessels can be divided into subtypes by antagonist affinity or by susceptibility to chloroethylclonidine or nifedipine. 2. Noradrenaline or phenylephrine produced concentration-dependent contractions in all the tissues tested, which were competitively inhibited by phentolamine, yohimbine, prazosin, WB4101 and HV723. However, there were large differences between the tissues in the pA2 values for all the antagonists except phentolamine. 3. The blood vessels could be classified into three groups (I, II and III) on the basis of their affinity variation. In group I (dog mesenteric artery and vein, saphenous vein), the pA2 values for HV723 were greater than 9, and those for HV723 and WB4101 were approximately 1 log unit higher than for prazosin. This rank order of affinity reversed in group II (dog carotid artery and rat thoracic aorta), where prazosin was more potent (pA2 values greater than 9.5) than HV723 or WB4101. In group III (rabbit mesenteric artery, thoracic aorta and carotid artery and guinea-pig thoracic aorta), on the other hand, prazosin, HV723 and WB4101 inhibited the noradrenaline response with a similar affinity (pA2 values ranging from 8 to 9). 4. Yohimbine inhibited the responses to noradrenaline and phenylephrine with a lower affinity than prazosin, HV723 or WB4101. The pA2 values for yohimbine were similar in groups I and II (the values greater than 6.5), which were greater than those in group III (values less than 6.4). 5. The alpha l-adrenoceptors in group II were selectively affected by chlorethylclonidine, resulting in an irreversible attenuation of noradrenaline responses in the dog carotid artery and a persistent contraction in the rat thoracic aorta. 6. Nifedipine either produced no effect or a slight inhibition of alpha l-adrenoceptor-mediated contractions in all the blood vessels; these effects were not correlated to the above groups. 7. These results suggest that alpha,-adrenoceptors of blood vessels can be divided into three subtypes (designated as alpha 1H, alpha4L and alpha 1N) by antagonist affinity and their susceptibility to chloroethylclonidine but not to nifedipine: the characteristics of each subtype are summarized in Table 3. Subtypes alpha lH, alpha 1L and alpha lN may be predominantly involved in the contractile responses to noradrenaline or phenylephrine of the blood vessels in groups II, III and I, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970493      PMCID: PMC1917493          DOI: 10.1111/j.1476-5381.1990.tb14678.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Catecholamine action on smooth muscle.

Authors:  E Bülbring; T Tomita
Journal:  Pharmacol Rev       Date:  1987-03       Impact factor: 25.468

2.  Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

3.  What do antagonists tell us about alpha-adrenoceptors?

Authors:  G M Drew
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

Review 4.  Evidence for and against heterogeneity of alpha 1-adrenoceptors.

Authors:  J P Hieble; R M DeMarinis; W D Matthews
Journal:  Life Sci       Date:  1986-04-14       Impact factor: 5.037

5.  The effect of reserpine on sympathetic, purinergic neurotransmission in the isolated mesenteric artery of the dog: a pharmacological study.

Authors:  I Muramatsu
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Pharmacological differentiation of postsynaptic alpha adrenoceptors in the dog saphenous vein.

Authors:  P J Fowler; M Grous; W Price; W D Matthews
Journal:  J Pharmacol Exp Ther       Date:  1984-06       Impact factor: 4.030

8.  Characterization of postjunctional alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-released norepinephrine in the canine saphenous vein.

Authors:  N A Flavahan; T J Rimele; J P Cooke; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1984-09       Impact factor: 4.030

9.  Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

10.  Differentiation of alpha 1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain.

Authors:  R D Johnson; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-03       Impact factor: 4.436

View more
  75 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

4.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Electrophysiologic and inotropic effects of alpha-adrenoceptor stimulation in human isolated atrial heart muscle.

Authors:  U Jahnel; H Jakob; H Nawrath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

6.  Investigations of the subtype of alpha 2-adrenoceptor mediating contractions of the human saphenous vein.

Authors:  K Smith; S Connaughton; J R Docherty
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

7.  Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction.

Authors:  H Chen; C Fetscher; R F Schäfers; G Wambach; T Philipp; M C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

8.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

9.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 10.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.